Fate Therapeutics To Present Clinical Data From Off-The-Shelf Anti-CD19 CAR T-Cell Product Candidate FT819, And Pre-Clinical Data From Anti-CD19 And CD38 CAR T-Cell Product Candidate FT839 At CCR – West Meeting

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced clinical data from its off-the-shelf anti-CD19 CAR T-cell product candidate FT819, and pre-clinical data from its off-the-shelf anti-CD19 and CD38 CAR T-cell product candidate FT839 will be featured at the Congress of Clinical Rheumatology West (CCR – West) meeting, being held in Huntington Beach, CA on September 17-20, 2026.

The Company is presenting encore clinical data from the systemic lupus erythematosus (SLE) study arm of its ongoing Phase 1 trial in support of its advancing RECLAIM-LN trial, a Phase 2 potentially registrational trial in lupus nephritis (LN). The presentation includes clinical safety, efficacy and translational data from 16 SLE patients treated in Regimen A of the Phase 1 trial, which is evaluating a single dose of FT819 combined with less-intensive, fludarabine-free conditioning chemotherapy, of whom 13 patients have completed at least one month of follow-up as of May 14, 2026 data cutoff.